191 related articles for article (PubMed ID: 35673560)
1. Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer.
Yu M; Wang H; Zhao W; Ge X; Huang W; Lin F; Tang W; Li A; Liu S; Li RK; Jiang SH; Xue J
Theranostics; 2022; 12(9):4386-4398. PubMed ID: 35673560
[No Abstract] [Full Text] [Related]
2. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
[TBL] [Abstract][Full Text] [Related]
3. Type Iγ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer.
Peng W; Huang W; Ge X; Xue L; Zhao W; Xue J
EBioMedicine; 2019 Jun; 44():375-386. PubMed ID: 31105034
[TBL] [Abstract][Full Text] [Related]
4. Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB.
Xue J; Chen C; Qi M; Huang Y; Wang L; Gao Y; Dong H; Ling K
Oncotarget; 2017 Jun; 8(26):42414-42427. PubMed ID: 28465490
[TBL] [Abstract][Full Text] [Related]
5. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
6. LncRNA
Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
[TBL] [Abstract][Full Text] [Related]
7. Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis.
Li C; Pan B; Wang X; Liu X; Qin J; Gao T; Sun H; Pan Y; Wang S
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1965-1982. PubMed ID: 35357586
[TBL] [Abstract][Full Text] [Related]
8. Augmented Antitumor Effect of Unripe
Lee EJ; Yang JH; Choi JG; Chung HS
Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
[TBL] [Abstract][Full Text] [Related]
9. Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer.
Ning T; Li J; He Y; Zhang H; Wang X; Deng T; Liu R; Li H; Bai M; Fan Q; Zhu K; Ying G; Ba Y
Mol Ther; 2021 Sep; 29(9):2723-2736. PubMed ID: 33905821
[TBL] [Abstract][Full Text] [Related]
10. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
11. Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis.
Yang K; Zhang J; Bao C
BMC Cancer; 2021 Aug; 21(1):933. PubMed ID: 34412616
[TBL] [Abstract][Full Text] [Related]
12. MGP promotes CD8
Rong D; Sun G; Zheng Z; Liu L; Chen X; Wu F; Gu Y; Dai Y; Zhong W; Hao X; Zhang C; Pan X; Tang J; Tang W; Wang X
Int J Biol Sci; 2022; 18(6):2345-2361. PubMed ID: 35414780
[TBL] [Abstract][Full Text] [Related]
13. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer.
Liao TT; Lin CC; Jiang JK; Yang SH; Teng HW; Yang MH
Theranostics; 2020; 10(14):6095-6112. PubMed ID: 32483441
[No Abstract] [Full Text] [Related]
14. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
[TBL] [Abstract][Full Text] [Related]
15. Exosomal transfer of circular RNA FBXW7 ameliorates the chemoresistance to oxaliplatin in colorectal cancer by sponging miR-18b-5p.
Xu Y; Qiu A; Peng F; Tan X; Wang J; Gong X
Neoplasma; 2021 Jan; 68(1):108-118. PubMed ID: 33147048
[TBL] [Abstract][Full Text] [Related]
16. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
[TBL] [Abstract][Full Text] [Related]
18. Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer.
Sun L; Patai ÁV; Hogenson TL; Fernandez-Zapico ME; Qin B; Sinicrope FA
Oncogene; 2021 Aug; 40(32):5105-5115. PubMed ID: 34193942
[TBL] [Abstract][Full Text] [Related]
19. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
20. Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.
Hua S; Gu M; Wang Y; Ban D; Ji H
Clin Transl Oncol; 2021 Apr; 23(4):750-756. PubMed ID: 32737836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
